Loading
NASDAQHealthcareBiotechnology
Latest quote
$40.28
+$0.68 · +1.72%
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Previous close
$40.28
+$0.68 · +1.72%
Regular session · ET · Market data may be delayed.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Day range
Current $40.28
52-week range
Current $40.28
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
86
Deep Value
Sentiment
71
Bullish
Risk
33
Moderate Risk
Momentum
58
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Day range
Current $40.28
52-week range
Current $40.28
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 868.45M USD | 714.73M USD | 582.02M USD | 437.86M USD | 305.44M USD |
| Cost of goods sold | 198.34M USD | 156.82M USD | 121.24M USD | 83.48M USD | 55.52M USD |
| Gross profit | 670.11M USD | 557.92M USD | 460.79M USD | 354.37M USD | 249.92M USD |
| Research and development | 189.59M USD | 145.83M USD | 76.06M USD | 70.89M USD | 30.37M USD |
| Selling, general, and administrative | 272.05M USD | 221.27M USD | 192.69M USD | 163.3M USD | 132.03M USD |
| Operating expenses | 461.64M USD | 367.09M USD | 268.76M USD | 234.19M USD | 162.39M USD |
| Interest income | 21.92M USD | 18.54M USD | 14.73M USD | 3.13M USD | 224K USD |
| Interest expense | 14.65M USD | 17.5M USD | 23.76M USD | 18.8M USD | 24.19M USD |
| Depreciation and amortization | 25.34M USD | 24.11M USD | 24.36M USD | 23.39M USD | 18.84M USD |
| Operating income | 208.47M USD | 190.83M USD | 192.03M USD | 120.19M USD | 87.53M USD |
| Net income | 158.69M USD | 145.49M USD | 128.85M USD | 181.47M USD | 34.6M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$49.00
21.65% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
